NEW YORK (GenomeWeb News) – Horizon Discovery and H3 Biomedicine today launched SyntheTx, a technology partnership created to provide novel oncology targets and early-stage drug discovery programs to drug manufacturers.

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical firm, is the first partner in the program. Additional partners will be sought in the first 12 to 18 months of the program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

Jul
19
Sponsored by
Philips Genomics

This webinar will provide an overview of how liquid biopsies can be integrated into lung cancer care.

Jul
20
Sponsored by
NuGEN

This webinar describes the characterization of gene fusions across distinct subtypes of melanoma.